News | August 28, 2025
FDA approves Coya Therapeutics’ trial of COYA 302 for ALS
As part of its partnership with Dr. Reddy’s Laboratories (DRL), FDA acceptance also triggers a $4.2 million milestone payment to Coya
As part of its partnership with Dr. Reddy’s Laboratories (DRL), FDA acceptance also triggers a $4.2 million milestone payment to Coya
The therapy delivers the full-length ABCA4 protein and has the potential to benefit all patients with ABCA4 mutations
FDA requests Sarepta Therapeutics to suspend distribution of Elevidys and places clinical trials on hold for multiple gene therapy products following 3 deaths
The IND application supports the next phase of development of SBO-154
Lexicon Pharmaceuticals announces exclusive license agreement with Novo Nordisk for LX9851
SIM0500 is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3
The primary objective of the study is to assess the safety and tolerability of SUVN-I6107 by monitoring adverse events (AEs), clinical laboratory, vital signs and electrocardiographs
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
Studies will Investigate Antidepressant Properties of Ketamir to Position for Initial IND Application in 2024
Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
